Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Vaccinations

Vaccinations

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

Vaccines

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Cross-reactivity

Cross-reactivity

Development of Immunocompetence

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Microbes can capture carbon and degrade plastic - why aren't we using them more?

Nature·2025

Same author

Europe needs a sustainably funded influenza research and response network.

The Lancet. Infectious diseases·2025

Same author

State of the Art and Emerging Technologies in Vaccine Design for Respiratory Pathogens.

Seminars in respiratory and critical care medicine·2025

Same author

Discovery and characterization of a pan-betacoronavirus S2-binding antibody.

Structure (London, England : 1993)·2024

Same author

Transforming vaccinology.

Cell·2024

Same author

Scientists' call to action: Microbes, planetary health, and the Sustainable Development Goals.

Cell·2024

Search research articles

Related Experiment Video

Updated: May 29, 2026

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes

Published on: July 26, 2019

The challenge of developing universal vaccines.

Rino Rappuoli¹

¹Novartis Vaccines and Diagnostics Via Fiorentina 1, 53100 Siena Italy.

F1000 Medicine Reports

|September 10, 2011

Summary

Developing universal vaccines against pathogens like Neisseria meningitidis, influenza, HIV, and Candida is challenging. Conserved antigens, while ideal for broad protection, are often poorly immunogenic due to pathogen evolution.

Area of Science:

* Pathogen immunology and vaccine development.
* Molecular mechanisms of immune evasion.
* Infectious disease and public health.

Background:

* Pathogens frequently evade immune responses through antigenic variability of key surface proteins.
* Universal vaccines targeting conserved antigens are a promising strategy for broad protection against diverse pathogen strains.
* Challenges exist in eliciting robust immune responses against conserved antigens selected for low immunogenicity.

Purpose of the Study:

* To review progress in developing vaccines for broad protection against Neisseria meningitidis, influenza, HIV, and Candida.
* To highlight the inherent difficulties in creating truly universal vaccines.
* To discuss the evolutionary basis for poor immunogenicity of conserved antigens.

Main Methods:

More Related Videos

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

Related Experiment Videos

Last Updated: May 29, 2026

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes

Published on: July 26, 2019

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

* Literature review of vaccine development strategies.
* Analysis of pathogen immune evasion mechanisms.
* Examination of evolutionary selection pressures on antigen immunogenicity.

Main Results:

* Significant advancements have been made in inducing broad immune responses against select pathogens.
* Truly universal vaccines remain difficult to produce due to conserved antigens being poorly immunogenic.
* Pathogen evolution actively selects against highly immunogenic conserved antigens.

Conclusions:

* Developing universal vaccines requires overcoming the challenge of poor immunogenicity of conserved antigens.
* Continued research is needed to design effective vaccines against highly variable pathogens.
* Understanding pathogen evolution is critical for successful vaccine design.